U.S. Stock Market Midday Update
Canopy Growth rose 12.57%, with increased trading volume. Based on recent news,
<ol>
<li>
On December 15, Canopy Growth announced it would acquire all issued and outstanding common shares of MTL Cannabis for approximately CAD 125 million in fully diluted equity value, and settle all debts and debt-like instruments of MTL. This transaction is expected to generate approximately CAD 10 million in synergies within 18 months. Following this announcement, Canopy Growth's stock price rose nearly 3%.
</li>
<li>
On December 15, Canopy Growth stated that this acquisition would strengthen its position in the Canadian medical market and deepen its presence in the key Canadian adult-use market. Following this announcement, Canopy Growth's stock price rose over 50% in Canada.
</li>
<li>
On December 16, Canopy Growth co-founder and Chief Cultivation Officer Richard Clément stated that this acquisition would enable MTL to expand its influence through Canopy's national distribution and retail relationships. Following this announcement, Canopy Growth's stock price continued to rise. The cannabis industry has been volatile recently, and investors should exercise caution.
</li>
</ol>
Top Stocks by Industry Trading Volume
Eli Lilly rose 0.13%, with increased trading volume. Based on recent key news:
<ol>
<li>
On December 15, Eli Lilly initiated Phase III clinical trials for Eloralintide, aimed at assessing its efficacy and safety in obese or overweight patients with type 2 diabetes. This move may enhance market confidence in its new drug development, driving stock price up. Source: Zhitong Finance
</li>
<li>
On December 15, Bank of America lowered Eli Lilly's target price from $128.6 to $126.8, reflecting market caution regarding its short-term profitability, which may exert some pressure on the stock price. Source: Bank of America
</li>
<li>
On December 16, Eli Lilly's stock price rose as Bank of America reaffirmed its buy rating, believing its leadership in obesity treatment and the upcoming oral GLP-1 drug will support its long-term growth. Source: Bank of America. The pharmaceutical industry is accelerating innovation, with significant capital inflow.
</li>
</ol>
Pfizer fell 1.23%, with increased trading volume. Based on recent key news:
<ol>
<li>
On December 16, Pfizer revised down its 2026 financial forecast, expecting a decrease in revenue from COVID products and the impact of patent expirations, causing its stock price to drop nearly 4%. Adjusted earnings per share fell short of analyst expectations, with nearly zero growth in annual revenue, indicating the company is in a rebuilding phase.
</li>
<li>
On December 17, U.S.-China trade tensions intensified, posing revenue challenges for Pfizer and risks of economic growth slowdown. Analysts believe the economy is still cooling moderately, not posing a recession risk, affecting market sentiment.
</li>
<li>
On December 17, the U.S. December Composite Purchasing Managers' Index showed a significant cooling in business activity growth momentum, rising inflation pressures, and increasing business costs, leading to relatively subdued market sentiment
The industry faces dual challenges of growth and inflation.
</li>
</ol>
Johnson &amp; Johnson rose 0.48%. Based on recent key news:
<ol>
<li>
On December 16, Bank of America Securities raised Johnson &amp; Johnson's target price from $204 to $220, maintaining a &#34;Neutral&#34; rating. This move reflects market confidence in Johnson &amp; Johnson's future growth potential, driving the stock price up.
</li>
<li>
On December 15, the U.S. FDA approved Johnson &amp; Johnson's new drug application for the treatment of BRCA2 mutation metastatic castration-sensitive prostate cancer. The drug showed significant efficacy in clinical trials, reducing the risk of disease progression or death, enhancing investor confidence in the company's R&amp;D capabilities.
</li>
<li>
On December 17, Royal Bank of Canada raised Johnson &amp; Johnson's target price from $230 to $240, further boosting market optimism towards Johnson &amp; Johnson. The pharmaceutical industry continues to innovate, with significant capital inflow.
</li>
</ol>
Stocks ranked at the top of the industry market capitalization
AstraZeneca fell 0.34%. Based on recent key news:
<ol>
<li>
On December 16, AstraZeneca's Saphnelo received FDA approval for the treatment of systemic lupus erythematosus, causing stock price fluctuations. This approval may enhance the company's market position in the immunology field, with the stock price dropping by 0.2%. Source: Business Wire
</li>
<li>
On December 17, AstraZeneca's Enhertu, in collaboration with Daiichi Sankyo, received FDA approval for first-line treatment of breast cancer, with trial results showing a significant improvement in progression-free survival. This news had a positive impact on the stock price, but overall market sentiment still led to a slight decline in the stock price. Source: Dow Jones Newswires
</li>
<li>
On December 17, AstraZeneca received permission to import Datopotamab Deruxtecan powder into India, demonstrating the company's efforts to expand in the global market. This move may have a positive impact on future revenue, but in the short term, the stock price remains affected by market fluctuations. Source: Alliance News The global pharmaceutical market is becoming increasingly competitive, with rising regulatory risks
</li>
</ol>

Canopy Growth rose 12.57%; Eli Lilly rose 0.13%, with a trading volume of USD 1.25 billion; Pfizer fell 1.23%, with a trading volume of USD 528 million; Johnson & Johnson rose 0.48%, with a trading volume of USD 509 million; AstraZeneca fell 0.34%, with a market value of USD 282.3 billion

U.S. Stock Market Midday Update: Canopy Growth Acquires MTL Cannabis, Stock Price Soars 12.57%